Christine R. Coyne - 01 Jul 2025 Form 4 Insider Report for Iterum Therapeutics plc (ITRM)

Reporting relationship: Chief Commercial Officer
Issuer ticker: ITRM
Reported as of: 01 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2025, 16:16:04 UTC
Prior SEC filing: 08 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Christine R. Coyne

Key filing fact

Christine R. Coyne filed Form 4 for Iterum Therapeutics plc (ITRM) on 03 Jul 2025.

Key facts

This page summarizes Christine R. Coyne's Form 4 filing for Iterum Therapeutics plc (ITRM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jul 2025, 16:16.

Change

Previous filing in this sequence was filed on 08 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861840 Primary reporting owner

Coyne Christine

Relationship: Chief Commercial Officer
Address: C/O 25 NORTH WALL QUAY, DUBLIN 1, IRELAND
Signature: /s/ Christine R. Coyne
Signature date: 03 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITRM transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 200,000
Exercise price: $0.9700
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of July 1, 2025 and the remaining 75% will vest in equal monthly installments thereafter until July 1, 2029, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.